sonepcizumab

for treatment of metastatic renal cell carcinoma

Also Known As:

LT-1009; LT1009; asonep; isonep

Networked: 5 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        sonepcizumab: 5
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        sonepcizumab: 5
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        sonepcizumab: 5

Experts

1.	Stoller, Glenn: 2 articles (02/2013 - 01/2009)
2.	Bhatt, Rupal S: 1 article (02/2017)
3.	Drabkin, Harry A: 1 article (02/2017)
4.	Hainsworth, John D: 1 article (02/2017)
5.	Hazel, Susan E: 1 article (02/2017)
6.	Paggiarino, Dario A: 1 article (02/2017)
7.	Pal, Sumanta K: 1 article (02/2017)
8.	Reeves, James A: 1 article (02/2017)
9.	Wojciak, Jon: 1 article (02/2017)
10.	Woodnutt, Gary: 1 article (02/2017)

Related Diseases

1.	Blister (Bulla) 02/01/2013 - "Analysis of variance with post hoc testing suggests a statistically significant trend of improvement in bleb duration for LT1009 when compared with BSS controls. " 02/01/2013 - "The mean duration of bleb survival was 28.5±8.5 days for rabbits receiving injections of LT1009, 21.0±5.6 days for those receiving injections of BSS, and 33.8±5.6 days for rabbits receiving MMC. " 02/01/2013 - "The monoclonal antibody LT1009 demonstrated a longer duration of bleb elevation than BSS control without adverse conjunctival effects associated with MMC. " 02/01/2013 - "The duration of bleb elevation was compared among LT1009, balanced saline solution (BSS) negative control, and mitomycin-C (MMC)-positive control. " 02/01/2013 - "This study examines the antifibrotic effects of the anti-S1P monoclonal antibody LT1009 (Sonepcizumab) in prolonging bleb survival in a rabbit model of glaucoma filtering surgery. "
2.	Carcinoma (Carcinomatosis) 11/01/2009 - "Using an in vitro bioassay, LT1002 and LT1009 were effective in blocking S1P-mediated release of the pro-angiogenic and prometastatic cytokine, interleukin-8, from human ovarian carcinoma cells, showing that both antibodies can out-compete S1P receptors in binding to S1P. "
3.	Choroidal Neovascularization 01/01/2009 - "In this study, we used a humanized monoclonal antibody (sonepcizumab) that selectively binds S1P to investigate its role in retinal and choroidal neovascularization (NV). "
4.	Glaucoma 02/01/2013 - "This study examines the antifibrotic effects of the anti-S1P monoclonal antibody LT1009 (Sonepcizumab) in prolonging bleb survival in a rabbit model of glaucoma filtering surgery. " 02/01/2013 - "Prevention of ocular scarring after glaucoma filtering surgery using the monoclonal antibody LT1009 (Sonepcizumab) in a rabbit model."
5.	Renal Cell Carcinoma (Grawitz Tumor) 02/15/2017 - "A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma." 02/15/2017 - "In this phase 2 study, the authors assessed the activity of sonepcizumab, a first-in-class inhibitor of S1P, in patients with metastatic renal cell carcinoma (mRCC) with a history of prior VEGF-directed therapy. "

Related Drugs and Biologics

1.	Interleukin-8 (Interleukin 8)
2.	Cytokines
3.	Antibodies
4.	Monoclonal Antibodies
5.	sonepcizumab
6.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
7.	Retinaldehyde (Retinal)
8.	sphingosine 1-phosphate (sphingosine-1-phosphate)
9.	Fluorescein (Funduscein)
10.	Mitomycin (Mitomycin-C)

Related Therapies and Procedures

1.	Filtering Surgery
2.	Therapeutics
3.	Intraocular Injections
4.	Lasers (Laser)
5.	Injections